Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia

Cancer

Volumn 119, Issue 24, 2013, Pages 4284-4289

  Johnson Ansah, Hyacinthe ^a   Guilhot, Joelle ^b   Rousselot, Philippe ^c   Rea, Delphine ^d   Legros, Laurence ^e   Rigal Huguet, Françoise ^f   Nicolini, Franck Emmanuel ^g   Mahon, François Xavier ^h   Preudhomme, Claude ⁱ   Guilhot, François ^b  

^a Department of Hematology   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c Hematology and Oncology Service   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f CHU PURPAN   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ Center for Biologic Pathology   (France)

Author keywords

chronic myeloid leukemia; clinical trial; imatinib; interferon; molecular response

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; IMATINIB; PEGINTERFERON ALPHA2A;

ARTICLE; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HUMAN; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; IMATINIB; INTERFERON; MOLECULAR RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PIPERAZINES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PYRIMIDINES; RECOMBINANT PROTEINS;

EID: 84889881855     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28328     Document Type: Article

References (22)

1. Bonifazi F, deVivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001; 98: 3074-3081.
2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of selective inhibitor of Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 335: 2408-2417.
4. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk of progression or events in patients in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009; 114:Pages. Abstract 1126.
5. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006; 108: 1478-1484.
6. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12: 841-851.
7. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119: 1123-1129.
8. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363: 2511-2521.
9. Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic leukemia patients in early phase. Haematologica. 2010; 95: 1415-1419.
10. Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011; 118: 3228-3235.
11. Cross NCP, White HE, Muller MC, Saglio G, Hochhaus A,. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26: 2172-2175.
12. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro. Blood. 2002; 99: 319-325.
13. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107: 4532-4539.
14. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL,. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34&plus CML cells. Blood. 2007; 109: 4016-4019.
15. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukaemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukaemia. 2007; 21: 926-935.
16. Bhattacharya S, Zheng H, Tzimas C, Carroll M, Baker DP, Fuchs SY,. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFN via accelerating the degradation of its receptor. Blood. 2011; 118: 4179-4187.
17. Essers MA, Offner S, Blanco-Bose WE, et al. IFN-alpha activates dormant haematopoietic stem cells in vivo. Nature. 2009; 458: 904-908.
18. Guilhot F, Roy L, Saulnier PJ, Guilhot J,. Interferon in chronic myeloid leukaemia: past and future. Best Pract Res Clin Haematol. 2009; 22: 315-329.
19. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011; 29: 1634-1642.
20. Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alpha maintenance after induction therapy with imatinib plus interferon alpha in patients with chronic myeloid leukemia. J Clin Oncol. 2010; 28: 1429-1435.
21. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28: 2381-2388.
22. Lipton JH, Khoroshko N, Golenkov A, et al. Phase II randomized, multicenter, comparative study of peginterferon-alpha-2a (40kD) (Pegasys) versus interferonalpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myeloid leukemia. Leuk Lymphoma. 2007; 48: 497-505.